FinancialContent is the trusted provider of stock market information to the media industry.
Latest News about Aducanumab
Biogen's Best-In-Class R&D Earn Makes It A Buy
October 17, 2017
Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail
January 30, 2017
Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
November 25, 2016
Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug
February 16, 2016
Wall Street Mixed On Biogen Before Earnings
July 23, 2015
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence...Even More Speculative Than Before'
July 22, 2015